Stock 1177 SINO BIOPHARMACEUTICAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Sino Biopharmaceutical Limited Share Price

Equities

1177

KYG8167W1380

Pharmaceuticals

Delayed Hong Kong S.E.
Other stock markets
 01:38:03 17/02/2025 GMT 		5-day change 1st Jan Change
3.330 HKD +3.10% Intraday chart for Sino Biopharmaceutical Limited +11.11% +3.12%
02-07 Chinese Regulator Approves Sino Biopharmaceul's Tulobuterol Patches for Marketing MT
02-07 Sino Biopharmaceutical's Anti-Inflammatory Medication Gets NMPA's Approval for Marketing MT

Valuation: Sino Biopharmaceutical Limited

Capitalization 54.73B 58.73B 7.55B 7.18B 6.78B 5.98B 10.69B 654B 11.86B 80.67B 29.89B 273B 28.29B 27.72B 1,147B P/E ratio 2024 *
16.5x
P/E ratio 2025 * 17.9x
Enterprise value 51.5B 55.27B 7.1B 6.76B 6.38B 5.63B 10.06B 615B 11.16B 75.91B 28.12B 257B 26.62B 26.08B 1,080B EV / Sales 2024 *
1.75x
EV / Sales 2025 * 1.46x
Free-Float
-
Yield 2024 *
2.07%
Yield 2025 * 2.43%
More valuation ratios * Estimated data

Chart: Sino Biopharmaceutical Limited

Dynamic Chart

Latest news: Sino Biopharmaceutical Limited

Chinese Regulator Approves Sino Biopharmaceul's Tulobuterol Patches for Marketing 02-07 MT
Sino Biopharmaceutical's Anti-Inflammatory Medication Gets NMPA's Approval for Marketing 02-07 MT
Sino Biopharmaceutical Limited Announces Approval for Marketing of the First Generic Tulobuterol Patches 02-07 CI
Sino Biopharm CEO Eric Tse on Outlook, Asian Pharmaceutical Market & Trump 01-23 MT
Sino Biopharmaceutical Limited commences an Equity Buyback Plan for 1,879,121,723 shares, representing 10% of its issued share capital, under the authorization approved on June 5, 2024. 01-08 CI
Sino Biopharm Reports Positive Results in NSCLC Drug's Phase III Study 12-27 MT
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection in Combination with Chemotherapy 12-26 CI
Sino Biopharm Cleared to Submit Marketing Application for New Indication of Tumor Drug 12-19 MT
Sino Biopharmaceutical's Cancer Drug Shows Positive Results in Clinical Trials 12-19 MT
Sino Biopharmaceutical Limited Obtains Permission to Submit Marketing Application for Indication of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for Treatment of Advanced Alveolar Soft Part Sarcoma 12-19 CI
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection with or Without Anlotinib Hydrochloride Capsules as Consolidation Therapy After Chemoradiotherapy for Non-Small Cell Lung Cancer 12-18 CI
Sino Biopharmaceutical Gets China Nod to Market Breast Cancer Drug 12-11 MT
Sino Biopharmaceutical Limited Announces Approval for Marketing of Eribulin Mesilate Injection 12-11 CI
More news

Analysts' recommendations: Sino Biopharmaceutical Limited

Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$6.42 From HK$6.16, Keeps at Buy 14/08/24 MT
Nomura Adjusts Sino Biopharmaceutical’s Price Target to HK$6.16 From HK$6.63, Keeps at Buy 15/03/24 MT
Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$6.63 From HK$7.43, Keeps at Buy 02/08/23 MT
Nomura Adjusts Sinobiopharma's Price Target to HK$7.43 From HK$7.78, Keeps at Buy 10/03/23 MT
UBS Adjusts Sino Biopharmaceutical's Price Target to HK$7.5 From HK$8, Keeps at Buy 25/08/22 MT
More recommendations

Press Releases: Sino Biopharmaceutical Limited

Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results 13/08/24 AQ
Sino Biopharmaceutical : 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 29/04/24 PU
Sino Biopharm (1177.HK) Announces 2023 Annual Results 29/03/24 AQ
Sino Biopharmaceutical (1177.HK) Announces 2023 Interim Results 25/08/23 AQ
Sino Biopharmaceutical : 2022 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 08/06/23 PU
More press releases

News in other languages: Sino Biopharmaceutical Limited

Borse Cina : chiudono miste, in rialzo Hong Kong con decisione su tassi 22/04/24
Las acciones de Hong Kong terminan planas tras una sesión volátil -- Market Talk 07/08/23
MÄRKTE ASIEN/Fester - Hoffen auf Zinspause 14/04/23
MÄRKTE ASIEN/Überwiegend aufwärts - Singapurer Zentralbank hält still 14/04/23
La actualización de la Lista Nacional de Medicamentos Reembolsables de China cumple las expectativas -- Market Talk 19/01/23
More news

Quotes and Performance

1 day+2.17%
1 week+11.11%
Current month+17.02%
1 month+14.58%
3 months+0.30%
6 months+9.27%
Current year+3.12%
More quotes

Course Extremes

1 week
2.94
Extreme 2.94
3.33
1 month
2.67
Extreme 2.67
3.33
Current year
2.67
Extreme 2.67
3.33
1 year
2.29
Extreme 2.29
4.25
3 years
2.29
Extreme 2.29
5.61
5 years
2.29
Extreme 2.29
11.24
10 years
2.01
Extreme 2.0148
11.24
More quotes

Managers and Directors: Sino Biopharmaceutical Limited

Director TitleAgeSince
S Y Tse CEO
 Chief Executive Officer 29 27/07/2022
Chun Ling Li DFI
 Director of Finance/CFO 54 31/12/1995
Hsin Tse IRC
 Investor Relations Contact 55 24/04/2013
Manager TitleAgeSince
Ping Tse CHM
 Chairman 73 01/02/2000
Hsin Tse BRD
 Director/Board Member 55 31/07/1995
Cheung Ling Cheng BRD
 Director/Board Member 61 09/04/2017
More insiders

ETFs: Sino Biopharmaceutical Limited

Name Weight AuM 1st Jan change Investor Rating
KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX UCITS ETF - USD ETF KraneShares MSCI All China Health Care Index UCITS ETF - USD
2.4% 0 M€ -20.08% -
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD ETF Loncar China BioPharma ETF - Distributing - USD
2.02% 0 M€ -27.92% -
KRANESHARES MSCI CHINA ESG LEADERS UCITS ETF ACC - USD ETF KraneShares MSCI China ESG Leaders UCITS ETF Acc - USD
0.82% 0 M€ -2.06% -
More ETFs: Sino Biopharmaceutical Limited

Other Pharmaceuticals

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi.($)
SINO BIOPHARMACEUTICAL LIMITED Stock Sino Biopharmaceutical Limited
+3.10%+11.11%+12.63%-39.67% 7.55B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
-3.00%-3.88%+7.95%+243.79% 760B
JOHNSON & JOHNSON Stock Johnson & Johnson
-0.70%+1.98%-0.26%-6.61% 376B
NOVO NORDISK A/S Stock Novo Nordisk A/S
-1.50%-11.35%-34.17%+73.38% 349B
ABBVIE INC. Stock AbbVie Inc.
-0.30%+1.19%+8.67%+32.22% 340B
ROCHE HOLDING AG Stock Roche Holding AG
-1.11%+1.90%+29.62%-13.94% 264B
ASTRAZENECA PLC Stock AstraZeneca PLC
-2.14%+0.93%+20.40%+39.70% 229B
MERCK & CO., INC. Stock Merck & Co., Inc.
-1.67%-4.89%-35.04%+7.50% 210B
NOVARTIS AG Stock Novartis AG
-2.46%-1.51%+8.62%+20.43% 210B
AMGEN INC. Stock Amgen Inc.
-1.16%-0.81%+2.63%+30.76% 157B
Average -1.19%-0.77%+2.11%+38.76% 290.15B
Weighted average by Cap. -1.72%-2.22%+1.53%+81.05%
See all sector performances

Financials

2024 *2025 *
Net sales 29.37B 31.52B 4.05B 3.86B 3.64B 3.21B 5.74B 351B 6.37B 43.29B 16.04B 147B 15.18B 14.87B 616B 32.34B 34.71B 4.46B 4.25B 4B 3.54B 6.32B 386B 7.01B 47.67B 17.66B 162B 16.72B 16.38B 678B
Net income 3.43B 3.68B 473M 450M 424M 375M 670M 40.95B 743M 5.05B 1.87B 17.12B 1.77B 1.74B 71.89B 3.12B 3.35B 430M 410M 387M 341M 610M 37.29B 677M 4.6B 1.7B 15.59B 1.61B 1.58B 65.46B
Net Debt -3.23B -3.47B -446M -424M -400M -353M -631M -38.6B -701M -4.76B -1.76B -16.14B -1.67B -1.64B -67.75B -7.66B -8.22B -1.06B -1B -948M -837M -1.5B -91.45B -1.66B -11.29B -4.18B -38.24B -3.96B -3.88B -161B
More financial data * Estimated data

Company Profile

Logo Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of cancer, ophthalmia, hepatitis, orthopedic diseases and respiratory disorders. Net sales break down by category of products as follows: - chemical medicine products and biopharmaceutical drugs (97.6%); - other (2.4%).
Employees
24,437
Sector
Pharmaceuticals
Calendar
27/03/2025 - Q4 2024 Earnings Release (Projected)
More about the company

Quotes

Date Price Change Volume
17/02/25 3.330 $ +3.10% 12,983,891
14/02/25 3.230 $ +5.21% 106,754,200
13/02/25 3.070 $ +0.99% 144,708,200
12/02/25 3.040 $ +3.40% 71,317,530
11/02/25 2.940 $ -2.65% 45,338,420

Delayed Quote Hong Kong S.E., February 17, 2025 at 01:38 am

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating
Investor Rating
ESG MSCI
A
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
3.010CNY
Average target price
4.183CNY
Spread / Average Target
+38.99%
Consensus
Profit revisions
Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. 1177 Stock
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition